Skip to content

Free cash flow at other companies

HRO
HarrowHROW
-$9.19M-147%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$6.11M+173%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$198M-18.6%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$52.3M+60.8%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
-$125.52M-40.0%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$59.56M-0.8%

Other financials

Income statement

See full
Revenue$24.3M+40.4%
Gross profit$14.7M+49.4%
Operating income$2.4M+614%
Net income$1.6M+199%
EPS (diluted)$0.05+183%

Balance sheet

See full
Cash & equivalents$19.7M+12.9%
Total debt$31.3M+3.7%
Total equity$30.6M+25.2%
Total assets$97.7M+16.3%

Cash flow

See full
Operating cash flow$7.4M+254%
CapEx$75.0K

Valuation

See full
Market cap$930.79M+156%
Enterprise value$942.39M+150%
P/S10.7×+3.2×

Profitability

See full
Gross margin54.8%-3.7pp
Operating margin-15.1%
Net margin-9.5%-2.7pp
FCF margin17.1%

Returns & leverage

See full
Return on equity-34.2%+0.9pp
Debt / equity-0.2×
Current ratio1.2×-0.8×

Where this comes from

Calculated from Eton Pharmaceuticals, Inc.’s reported figures.

The official record: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eton Pharmaceuticals, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eton Pharmaceuticals, Inc.'s free cash flow?
Eton Pharmaceuticals, Inc. (ETON) reported free cash flow of $7.33M in Q1 2026.
How has Eton Pharmaceuticals, Inc.'s free cash flow changed year-over-year?
Eton Pharmaceuticals, Inc.'s free cash flow increased by 250.7% year-over-year, from $2.09M to $7.33M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.